You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company announced the submission of two New Drug Applications (NDAs) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic (semaglutide). Seeking approval for an indication for the treatment of adultAlready a subscriber Login You have read…
Calliditas Therapeutics has announced that a $5 million milestone payment from its partner Everest Medicines II Limited has been triggered as per the licensing agreement under which Everest is to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore. Already a subscriber Login You have read…
Lobsor Pharmaceuticals has announced that Lecigon has been approved, and that the Swedish Medical Products Agency (MPA) has confirmed End of Procedure according to the European Mutual Recognition Procedure (MRP) including Denmark, Finland and Norway. "We are delighted to have now received confirmAlready a subscriber Login You have read all…
Nuevolution announces that Janssen Biotech has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015, a collaboration that was expanded further in April 2016 and March 2017. The program that has been licenAlready a subscriber Login You have read all your free…
